Effect of Buparlisib, a Pan-Class I PI3K Inhibitor, in Refractory Follicular and Poorly Differentiated Thyroid Cancer.
Borson-Chazot F, Dantony E, Illouz F, Lopez J, Niccoli P, Wassermann J, Do Cao C, Leboulleux S, Klein M, Tabarin A, Eberle MC, Benisvy D, de la Fouchardière C, Bournaud C, Lasolle H, Delahaye A, Rabilloud M, Lapras V, Decaussin-Petrucci M, Schlumberger M.
Borson-Chazot F, et al. Among authors: dantony e.
Thyroid. 2018 Sep;28(9):1174-1179. doi: 10.1089/thy.2017.0663.
Thyroid. 2018.
PMID: 30105951
Clinical Trial.